Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.57 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA4 | P22748 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6980785 | 0.98 | CA12 (0.59) | CA12CA1CA2CA4CA9 | |
| Hydrochloric Acid SCHEMBL27480577 | 0.91 | POLB (0.57) | CA12CA1CA2CA4CA9 | |
| SCHEMBL7347503 | 0.89 | ITGB3 (0.60) | CA12CA1CA2CA4CA9 | |
| SCHEMBL3081465 | 0.84 | KMT2A (0.55) | CA1CA2KMT2AMEN1L3MBTL1 | |
| SCHEMBL3093136 | 0.84 | KMT2A (0.55) | CA1CA2KMT2AMEN1L3MBTL1 | |
| SCHEMBL7423108 | 0.84 | CA12 (0.44) | CA12CA1CA2CA4CA9 | |
| SCHEMBL7345488 | 0.84 | ITGB3 (0.54) | CA12CA1CA2CA4CA9 | |
| SCHEMBL7423126 | 0.83 | POLB (0.45) | CA12CA1CA2CA4CA9 | |
| SCHEMBL7346087 | 0.82 | ITGB3 (0.53) | CA12CA1CA2CA4CA9 | |
| SCHEMBL7347966 | 0.82 | POLB (0.44) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030054029-A1 | IIB/IIIA ANTAGONISTS CO-ADMINISTERED WITH ASPIRIN | WESTERN MICHIGAN UNIVERSITY | 2003-03-20 | — | — | US | disclosed |
| EP-0630366-B1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS | SEARLE & CO (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-0835265-B1 | PLATELET AGGREGATION INHIBITORS CONTAINING C-TERMINAL AMINERGIC SIDE CHAIN AMINO ACID RESIDUES | SEARLE & CO (US) | 2002-08-07 | — | — | EP | disclosed |
| CN-1087283-C | Novel LH-RH antagonists with improved action | ZANTARIS AG (DE) | 2002-07-10 | — | — | CN | disclosed |
| EP-0542708-B1 | Substituted beta-amino acid derivatives useful as platelet aggregation inhibitors | MONSANTO CO (US) | 2001-05-30 | — | — | EP | disclosed |
| EP-0539343-B1 | Substituted heterocyclic derivatives useful as platelet aggregation inhibitors | MONSANTO CO (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0839128-B1 | PROCESS FOR THE PREPARATION OF ETHYL 3S-[[4-[[4-(AMINOIMINOMETHYL)PHENYL]AMINO]-1,4-DIOXOBUTYL]AMINO]-4-PENTYNOATE | SEARLE & CO (US) | 2000-04-05 | — | — | EP | disclosed |
| US-6037365-A | ANTIINFLAMMATORY AND ANTIMETASTASIS AGENTS; CARDIOVASCULAR DISORDERS, ARTERIOSCLEROSIS | G.D. SEARLE & CO. (US) | 2000-03-14 | — | — | US | disclosed |
| US-5973003-A | TREATMENT OF THROMBOSIS, STROKE, MYOCARDIAL INFARCTION, INFLAMMATION AND ARTERIOSCLEROSIS | G. D. SEARLE & CO. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5942493-A | LH-RH antagonists having improved action | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-08-24 | — | — | US | disclosed |
| EP-0630366-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS | G.D. Searle & Co. (US) | 1994-12-28 | — | — | EP | disclosed |
| EP-0614360-A1 | SUBSTITUTED -g(b)-AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS. | SEARLE & CO (US) | 1994-09-14 | — | — | EP | disclosed |
| US-5344957-A | Amidinoiphenyl-substituted | G.D. SEARLE & CO. (US) | 1994-09-06 | — | — | US | disclosed |
| US-5254573-A | Substituted heterocyclic derivatives useful as platelet aggregation inhibitors | MONSANTO COMPANY (US) | 1993-10-19 | — | — | US | disclosed |
| WO-1993018058-A1 | PEPTIDES MIMICS USEFUL AS PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1993-09-16 | — | — | WO | disclosed |
| US-5239113-A | Anticoagulants | MONSANTO COMPANY (US) | 1993-08-24 | — | — | US | disclosed |
| EP-0542708-A1 | Substituted B-amino acid derivatives useful as platelet aggregation inhibitors | MONSANTO COMPANY (US) | 1993-05-19 | — | — | EP | disclosed |
| WO-1993007867-A1 | SUBSTITUTED β-AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1993-04-29 | — | — | WO | disclosed |
| WO-1993008164-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1993-04-29 | — | — | WO | disclosed |
| EP-0539343-A1 | Substituted heterocyclic derivatives useful as platelet aggregation inhibitors | MONSANTO COMPANY (US) | 1993-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030054029-A1 | IIB/IIIA ANTAGONISTS CO-ADMINISTERED WITH ASPIRIN | F13B, FGB, F2R | CA2 1819/4885BCHE 4140/4885CA12 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.